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Summary 
The immunosuppressant drug FK506 binds to the im- 
munophilin protein FKBPl2 and inhibits its prolyl iso- 
meraseactivity. Immunosuppresiveactions, however, 
are mediated via an FK506-FKBP12 inhibition of the 
Ca*+-activated phosphatase calcineurin. Physiologic 
cellular roles for FKBPl2 have remained unclear. 
FKBPl2 is physically associated with the RyR and IP3R 
Ca*+ channels in the absence of FK506, with added 
FK506 disrupting these complexes. Dissociation of 
FKBPl2 results in alteration of channel Ca% conduc- 
tance in both cases. We now report that calcineurin is 
physiologically associated with the IP3R-FKBP12 and 
RyR-FKBP12 receptor complexes and that this inter- 
action can be disrupted by FK506 or rapamycin. Cal- 
cineurin anchored to the IP3R via FKBP12 regulates 
the phosphorylation status of the receptor, resulting 
in a dynamic Ca*+ -sensitive regulation of IP3-mediated 
Ca2+ flux. 
Introduction 
The immunophilin proteins mediate the clinical effects of 
the immunosuppressant drugs cyclosporin A, FK506, and 
rapamycin. Cyclophilins, thefirstclassof immunophilinsto 
be identified, bind to cyclosporin A, acyclic undecapeptide 
(Handschumacher et al., 1984; for review see Walsh et 
al., 1992). FK506 and rapamycin, structurally related mac- 
rolides, instead bind to the FK506-binding protein (FKBP) 
class of immunophilins. Although there are a number of 
membersoftheimmunophilinfamily, immunosuppressant 
actions appear largely attributable to cyclophilin A and 
B and FKBP12 (Bram et al., 1993). The cyclophilins and 
FKBPs do not share amino acid sequence similarity, but 
both display peptidylprolyl-cis-trans isomerase (rota- 
mase) activity thought to be associated with protein folding 
(Schmid, 1993). Furthermore, immunophilin rotamase ac- 
tivity is inhibited by their respective immunosuppressant 
ligands. lmmunosuppressant actions, however, do not ap- 
pear to derive from inhibition of this isomerase activity. 
Rather, the drug-immunophilin complex of cyclosporin 
A-cyclophilin or FK506-FKBP12 binds to the protein 
phosphatase calcineurin to inhibit its activity, thereby aug- 
menting levels of phosphorylated calcineurin substrates 
such as the transcription factor NFAT (for nuclear factor 
of activated T cells) (Liu et al., 1991; O’Keefe et al., 1992; 
Clipstone and Crabtree, 1992; for review of calcineurin, 
see Klee et al., 1988). In its phosphorylated state, NFAT 
cannot translocate to the nucleus, where it regulates ex- 
pression of genes critical for T cell activation such as in- 
terleukin-2 (IL-2). Rapamycin acts differently than cyclo- 
sporin A and FK506, as it blocks the actions of IL-2 rather 
than its synthesis (Bierer et al., 1990). Rapamycin binds 
with high affinity to FKBP12 and inhibits its rotamase activ- 
ity, but the rapamycin-FKBP12 complex does not interact 
with calcineurin. Rather, this immunosuppressant-immu- 
nophilin complex binds to a recently identified target pro- 
tein designated RAFT (for rapamycin and FKBP12 target) 
or FRAP (for FKBP-rapamycin-associated protein) (Sa- 
batini et al., 1994; Brown et al., 1994). 
Marks and colleagues have observed an association 
of FKBP12 with the ryanodine receptor (RyR) of skeletal 
muscle in the absence of FK506 (Jayaraman et al., 1992; 
Timerman et al., 1993; Brillantes et al., 1994). RyR is a 
tetrameric Ca*+ channel that mediates Ca’+-induced Ca2+ 
release in muscle, brain, and other tissues (Takeshima 
et al., 1989; McPherson and Campbell, 1993). We have 
demonstrated that the inositol 1,4,5-trisphosphate (IP,) re- 
ceptor (IPBR), a structurally and functionally related tetra- 
merit Ca2+ channel that shares up to 40% homology to 
RyR in some regions, is also a direct target of FKBP12 
(Cameron et al., 1995; for review see Furuichi and Miko- 
shiba, 1995; Snyder and Sabatini, 1995). Whereas FK506 
stimulates the binding of FKBP12 to calcineurin, FK506 
dissociates FKBP12 from RyR and from IP$R. When 
FKBP12 is “stripped” from the RyR-FKBPlP or IP3R- 
FKBP12 complex, the Ca2+ channels of these two proteins 
become “leaky.” Accordingly, net accumulation of Ca’+ 
into RyR-or IPsR-gated stores is diminished, and releasing 
agents such as caffeine or IPa cause increased Ca*+ flux at 
lower concentrations. It was assumed that the isomerase 
activity of FKBP12 was the means by which this protein 
modulates the RyR and IP3R. However, recent evidence 
obtained from mutant FKBP12 proteins lacking isomerase 
activity suggests that this is not the case (Timerman et 
al., 1995). Accordingly, we have attempted to investigate 
alternative means by which FKBP12 modulates IP,R- and 
RyR-mediated Ca*+ flux. 
IP3R can be phosphorylated at three distinct sites by 
protein kinase C (PKC), Caz+/calmodulin~dependent pro- 
tein kinase II (CaMKII), and cyclic AMP-dependent protein 
kinase (PKA), respectively (Ferris et al., 1991). Whether 
phosphorylation and dephosphorylation physiologically 
regulate IP,R function has not been established. The asso- 
ciation of FKBP12 with IP3R suggested a potential func- 
tional link of calcineurin and IP3R. We now demonstrate a 
physical association of calcineurin with the IP,R-FKBP12 
and RyR-FKBP12 complexes that is potently disrupted 
by treatment with FK506 or rapamycin. We also show that 
complexed calcineurin modulates the phosphorylation 
status and Ca’+ flux properties of IP3R. 
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Results 
Copurification and Coimmunoprecipitation 
Demonstrate an FKSOBSensitive Association 
of Calcineurin with IP3R and RyR 
To look for an association of calcineurin with IP3R, we 
purified lPBR from rat cerebellum to apparent homogeneity 
by sequential fractionation on heparin and concanavalin 
A columns as previously described (Ferris et al., 1989). 
The purified receptor was then subjected to further frac- 
tionation on a fast protein liquid chromatography (FPLC) 
Superose 6 column, which separates proteins according 
to their molecular mass. Purified IP& immunoreactivity 
is concentrated in fractions 9-12 (Figure lA), an elution 
FPLC fraction # 
A 
B 
C 
D 
Figure 1. Copurification of Calcineurin with IP,R Is Disrupted by Treat- 
ment with Rapamycin 
In (A), (B) and (D), purified preparations of IP,R were subjected to 
FPLC gel filtration and analyzed via Western blot analysis. 
(A) shows the majority of lPBR immunoreactivity in FPK fractions 9- 
12, as reported previously (Cameron et al., 1995). 
(B) shows that calcineurin (CN) immunoreactivity is observed in these 
same samples and closely parallels the distribution of IP,R immunore- 
activity. 
(C) shows that pure calcineurin, fractionated in an identical fashion, 
elutes in fractions 18 and 19. 
(D) shows that IP3R fractions treated with rapamycin before FPLC 
fractionation contain calcineurin immunoreactivity in lanes 18 and 19. 
point that reflects the molecular mass of the IP3R tetramer, 
which is greater than 1.2 x 1 O6 Da. Subjecting the identical 
FPLC fractions to Western blot analysis with an antibody 
specific for calcineurin reveals that calcineurin immunore- 
activity closely parallels the distribution of IP3R (Figure 
1B). lmmunoreactivity for both IP3R and calcineurin is 
blocked by preabsorption with antigen (data not shown). 
Thus, not only is calcineurin present in a highly purified 
preparation of IPzR, but when such a preparation is frac- 
tionated by gel filtration calcineurin comigrates with the 
lPBR even though its molecular mass is only 10% that of 
the IP3R tetramer. In contrast, when pure calcineurin is 
fractionated by FPLC in an identical fashion, calcineurin 
immunoreactivity migrates in fractions 18-19, a later elu- 
tion point more consistent with a protein of molecular mass 
around 80 kDa (Figure 1C). Treating our preparation of 
IPzR with rapamycin, which disrupts the IP3R-FKBP12 in- 
teraction (Cameron et al., 1995), before FPLC fraction- 
ation causes calcineurin immunoreactivity to shift back to 
fractions 18 and 19 (Figure 1 D), while the IP3R continues 
to run in fractions 9-12 (data not shown). 
We also demonstrate the specific association of cal- 
cineurin with IP3R and RyR by immunoprecipitation ex- 
periments. We employed antibodies to IP9R with crude 
preparations of rat cerebellar membranes. The immuno- 
precipitate displays immunoreactive calcineurin as well as 
IP3R (Figure 2). Inclusion of increasing concentrations of 
FK506 in the membrane preparation decreases the 
amount of calcineurin in the immunoprecipitate. Quantifi- 
cation of band intensity reveals that half-maximal reduc- 
tion of the presence of calcineurin in the immunoprecipi- 
tate occurs between 10 and 100 nM FK506. This range 
is similar to the ECso obtained for FK506 dissociation of 
FKBP12 from RyR reported by Timerman and colleagues 
to be in the range of 120-500 nM (Timerman et al., 1993). 
Cyclosporin A fails to influence the calcineurin content of 
the immunoprecipitate, while rapamycin, which like FK506 
binds tightly to FKBP12, markedly reduces the calcineurin 
content of the immunoprecipitate. The association of cal- 
cineurin with the IP,R-FKBP12 complex appears to re- 
quire Ca’+, as EGTA depletes the calcineurin content of 
the immunoprecipitate (Figure 2). Control immunopre- 
cipitation experiments were carried out with antibodies 
against calbindin and microtubule-associated protein 2 
(MAP-P), which like IPsR are proteins of high abundance 
in cerebellar Purkinje cells. Calcineurin immunoreactivity 
was not seen in the immunoprecipitate in either case, nor 
in experiments using the anti-lP3R antibody preimmune 
serum (Figure 2). 
We have also demonstrated a similar association of cal- 
cineurin with RyR (Figure 3A). lmmunoprecipitation of cer- 
ebellar homogenates with anti-RyR antibodies results in 
coprecipitation of calcineurin. Both FK506 and EGTA de- 
plete the immunoprecipitate of calcineurin. The associa- 
tion of calcineurin with IPsR and RyR is further supported 
by immunoprecipitation experiments conducted with anti- 
bodies to calcineurin (Figure 3B). In these experiments, 
IP3R and RyR immunoreactivity is apparent in the cal- 
cineurin immunoprecipitate. Treatments with either FK506 
or EGTA prevent the appearance of IP,R or RyR in the 
Calcineurin-IPR-FKBP Complex and Ca2+ Flux 
465 
Relative amount of calcineurtn present in immunoprecipitate 
Figure 2. Coimmunoprecipitation of Calcineurin with IPR Is Ca*+ De- 
pendent and FK506 Sensitive 
A crude homogenate was prepared from rat cerebellum and used for 
coimmunoprecipitation assays. lmmunoprecipitationswere performed 
as described and analyzed via Western blot analysis as indicated. 
lmmunoprecipitation with an antibody specific for IP,R precipitates 
calcineurin (CN) (middle panel), as well as lPBR (upper panel). The 
calcineurin coimmunoprecipitation is blocked by the inclusion of in- 
creasing amounts of FK506, rapamycin, or EGTA (20 mM), but not by 
cyclosporin A (CsA), whereas a constant amount of IP,R is present 
in each immunoprecipitate. Relative intensity of immunoreactive cal- 
cineurin bands was quantified and is shown in the lower panel for 
each condition, giving an EC& of dissociation of FKBP12 from IP3R 
in the range of IO-100 nM FK506. Control immunoprecipitations using 
antibodies against calbindin and MAP-2 under identical conditions did 
not coimmunoprecipitate calcineurin (shown in panel on right). 
immunoprecipitate. Probing the calcineurin immunopre- 
cipitate with anti-MAP-2 or anti-calbindin antibodies via 
Western blot analysis shows no evidence of either of those 
two proteins in the calcineurin immunoprecipitate (data 
not shown). 
Calcineurin Activity in IPaR-FKBP12-Calcineurin 
Complex Regulates Phosphorylation Status 
of IP,R 
To ascertain whether calcineurin associated with the 
IP3R-FKBPl 2 complex retains catalytic activity, we devel- 
oped a substrate-specific assay for calcineurin phospha- 
tase activity. We first used a known calcineurin substrate, 
MAP-2, phosphorylated by PKA. Addition of purified cal- 
cineurin together with Cd+ and calmodulin markedly re- 
duces phosphorylation of MAP-2 (Figure 4A). EGTA pre- 
vents this activity. Addition of FK506 and FKBP12 inhibits 
calcineurin activity, whereas FKBPlP alone has no effect. 
Likewise, addition of FK506 or rapamycin alone does not 
alter calcineurin activity (data not shown). This is consis- 
Figure3. Calcineurin Coimmunoprecipitates with RyR in a Ca*+- 
Dependent and FK506-Sensitive Manner 
(A) Demonstrates an experiment identical to that shown in Figure 2, 
but performed with an antibody specific for RyR. Calcineurin (CN) 
coimmunoprecipitation (lower panel) with RyR (upper panel) is blocked 
by the inclusion of FK506 or EGTA (20 mM), whereas RyR is present 
in the immunoprecipitate in constant amounts. 
(B) Shows an immunoprecipitation experiment using an antibodyspe- 
cific for calcineurin. While the upper panel demonstrates equal cal- 
cineurin content in the immunoprecipitates, the lower panel demon- 
strates that IP,R or RyR will coimmunoprecipitate unless FK506 or 
EGTA (20 mM) is added. 
tent with previous observations that the FK506-FKBP12 
complex, but neither molecule alone, inhibits calcineurin 
activity(Liu et al., 1991). Whereas rapamycin binds tightly 
to FKBPlP, the complex does not interact with calcineurin 
(Liu et al., 1991). Addition of rapamycin and FKBP does 
not inhibit calcineurin activity in our assay. Cyclosporin 
A added with FKBP12 also does not inhibit calcineurin 
activity, consistent with the inability of cyclosporin A to 
bind to FKBP12. Analysis with a phosphorimager permits 
consistent quantification of the degree of phosphorylation 
of MAP-2 and thus determination of calcineurin activity 
against a specific substrate under varying experimental 
conditions (Figure 48). 
Our purified IPR preparations possess calcineurin ac- 
tivity (Figure 5A). In the presence of Caz+ and calmodulin, 
IP3R preparations dephosphorylate MAP-2 with the same 
activity as purified calcineurin (units of phosphatase activ- 
ity per milligram of calcineurin addedor present in prepara- 
tion). EGTA blocks this dephosphorylation. Addition of 
cyclosporin A and cyclophilin also inhibits phosphatase 
activity, as does addition of calcineurin autoinhibitory pep- 
tide or deltamethrin, all of which are known to be potent 
inhibitors of calcineurin activity (Liu et al., 1991; Hashi- 
moto et al., 1990; Enan and Matsumura, 1992). Treatment 
of calcineurin or IP3R preparations with permethrin, a non- 
inhibiting analog of deltamethrin (Enan and Matsumura, 
1992) or okadaic acid, a protein phosphatase inhibitor not 
active against calcineurin at low concentrations (Bialojan 
and Takai, 1988) does not inhibit observed phosphatase 
activity. Pretreatment of IP3R preparations with FK506 
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MAP-2 
Figure 4. Measurement of Calcineurin Phosphatase Activity Toward 
a Specific Protein Substrate, Evaluated with MAP-Z 
MAP-Z was phosphorylated by PKA using radiolabeled ATP as de- 
scribed, and the reaction was stopped by addition of 10 NM Walsh 
inhibitor. Phosphorylated MAP-2 was then incubated with calcineurin 
(CN, 2 PM) for 30 min at 37O. Ca2+ (100 KM) and calmodulin (4 NM) 
(indicated by an asterisk), EGTA (20 mM), FKBP12 (1 NM), FK506 (1 
KM), cyclosporin A (CsA, 1 PM), or rapamycin (1 MM) were included 
in the calcineurin reaction as indicated. The reactions were terminated 
with 5 x sample buffer, and SDS-PAGE was performed. Gels were 
dried down and exposed on a Molecular Dynamics phosphorrmager, 
which allowed identification of radiolabeled MAP-2 as shown in (A) 
and quantitation of MAP-2 phosphorylation as shown in (8). This exper- 
iment was repeated four times with essentially the same results. 
alone blocks the calcineurin activity seen in the complex. 
This is consistent with FK506 binding to the FKBPlP con- 
tained in the IP,R complex and inhibiting activity of the 
associated calcineurin. By contrast, pretreatment of IPJI 
preparations with rapamycin fails to inhibit the associated 
calcineurin activity. Treatment of the complex with rapa- 
mycin also disrupts the IPR-FKBP12 interaction and thus 
liberates calcineurin from the complex. The retention of 
calcineurin activity in these preparations is consistent with 
the failure of the rapamycin-FKBPlP complex to bind to 
and inhibit calcineurin. 
IPR can be phosphorylated by PKA, CaMKll, and PKC, 
with the three enzymes phosphorylating at three distinct 
sites (Ferris et al., 1991). Purified lPBR phosphorylated by 
PKA is a substrate for exogenously added calcineurin 
(data not shown). Also, purified IPsR preparations display 
H PKA PKC 
IP3R-W 
LT I.25 I 
Figure 5. Purified Preparations of IP$f Display Calcineurin Activity 
against MAP-2 and against Complexed IP3R Itself 
IP,R was purified as described and assayed for calcineurin (CN) activ- 
ity against MAP-2 as described above. 
(A) shows that no pretreatment or pretreatment of the preparation with 
rapamycin did not affect calcineurin activity, indicating that complexed 
calcineurin is catalytically active. Pretreatment of preparations with 
FK506 (1 mM) inhibited calcineurin activity. Pure calcineurin, as well 
as phosphatase activity from lPBR preparations, was sensitive to 
cyclosporin A (CsA, 1 mM), calcineurin autoinhibitory peptide (100 
mM), and deltamethrin (1 nM). Phosphatase activity was not inhibited 
by permethrin (1 nM) or okadaic acid (500 nM), both of which are 
known to be inactive against calcineurin. 
(B) shows phosphorylation of purified IP$f with PKA, CaMKII, or PKC 
as indicated. The inclusion of a specific calcineurin inhibitor (1 mM 
cyclosporin A and 1 mM cyclophilin) modestly enhances phosphoryla- 
tion by PKA and CaMKll and dramatically increases phosphorylation 
by PKC, demonstrating that IP,R itself is a substrate for complexed 
calcineurin. The asterisk indicates a significant difference in the case 
of PKA and PKC (p < ,005). This experiment was repeated four times 
with essentially the same results. 
calcineurin activity toward PKA-phosphorylated IP3R (data 
not shown). Accordingly, we directly examined whether 
complexed calcineurin is catalytically active toward asso- 
ciated IP3R that has been phosphorylated by PKA, CaM- 
KII, and PKC. Since active calcineurin is already in a com- 
plex with purified IP3R, the effects of its phosphatase 
activity on IP3R are difficult to study. Instead, we ascer- 
tained whether treatment with cyclosporin A and cyclophi- 
lin, which together inhibit calcineurin, would alter the phos- 
phorylation status of phosphorylated IP3R (Figure 58). In 
the absence of cyclosporin A-cyclophilin treatment, the 
level of phosphorylation of IP3R is about the same for PKA 
and CaMKII, but is much lower for PKC. This fits with 
our earlier studies in which it was very difficult to detect 
substantial phosphorylation of purified IP3R with PKC (Su- 
pattapone et al., 198813; Ferris et al., 1991). Treatment with 
cyclosporin A and cyclophilin increases the final observed 
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Figure 6. Effects of Calcineurin Inhibition on Enhancement of IPsR 
Phosphorylation Parallel Actions on IPa-Mediated Ca2+ Flux 
Rat cerebellar microsomeswere prepared as described and phosphor- 
ylated by PKA, CaMKII, or PKC as indicated. Aspecific kinase inhibitor, 
control vehicle, or calcineurin inhibitor (1 mM cyclosporin A [CsA] and 
1 mM cyclophilin) was included in the phosphorylation reaction, and 
the final phosphorylation status of the lPIR was determined (shown 
on the left) along with IP3R-mediated Ca2+ flux properties (shown on 
the right) for each condition. 
(A) shows that PKA phosphorylation of lPBR resulted in a decreased 
potency of IPs in causing Ca2+ flux, but neither degree of phosphoryla- 
tion nor Ca*+ flux characteristics were altered by inhibition of cal- 
cineurin. 
(8) shows that CaMKII-phosphorylated membranes demonstrated an 
increased potency of IP3-mediated Ca2+ flux, but calcineurin inhibition 
did not significantly alter phosphorylation status or Ca2+flux character- 
istics of IP3R. 
(C)shows a pronounced enhancement of PKC phosphorylation of IP3R 
by calcineurin inhibition, which was paralleled by a similar increase 
in the potency of IPa in fluxing Ca2+ from PKC-phosphorylated mem- 
branes in the presence of acalcineurin inhibitor. The asterisk indicates 
that only for PKC did inhibition of calcineurin result in a significant 
effect on IP,R phosphorylation and Caz+ flux. This experiment was 
repeated four times with essentially the same results. 
(D) shows measurement of PKC catalytic activity toward a substrate, 
myelin basic protein, amino acids 4-14, which is not dephosphorylated 
by calcineurin. Thus, inclusion of activated calcineurin in the presence 
or absence of calcineurin inhibitors allows for assessment of the effect 
of calcineurin phosphatase activity on PKC kinase activity itself. No 
level of phosphorylation by PKC more than lo-fold, while 
only modestly increasing phosphorylation by PKA and 
CaMKII. 
Phosphorylation and Calcineurin-Mediated 
Dephosphorylation Regulate 
IP&Associated Ca2+ Flux 
We examined the influence of phosphorylation status 
upon Ca*+ flux mediated by IP3R utilizing cerebellar micro- 
some preparations. We previously demonstrated IPs- 
induced Ca’+ flux in purified IP3R reconstituted into lipid 
vesicles (Ferris et al., 1989). However, the additional ma- 
nipulations involved in phosphorylating the receptor pro- 
tein degrade the Ca*+ flux system, precluding analysis of 
phosphorylation influenceson Ca2+flux using purified IP3R 
in lipid vesicles. Microsome preparations made from rat 
cerebellum load Ca2+ in a time- and ATP-dependent fash- 
ion into IPs-sensitive and IP3-insensitive stores. IPs-sensitive 
stores comprise approximately 60% of the total in these 
preparations, and addition of varying concentrationsof IP, 
during loading will cause a net reduction in Ca’+ uptake 
via an outward flux through IP3R. This IP3-sensitive inhibi- 
tion of loading is consistently and reproducibly observed 
and allows for assessing potency of submaximal doses 
of IPs in stimulating Ca*+ flux via IP3R under a variety of 
experimental conditions (for further explanation of %a2+ 
flux assays, see Experimental Procedures). The potency 
of IPs in augmenting Ca2+ flux from microsomes is dimin- 
ished in preparations treated with PKA when compared 
with matched preparations treated with PKA in the pres- 
ence of Walsh inhibitor of phosphorylation (Figure 6A). 
These findings confirm our earlier observations (Supatta- 
pone et al., 1988b). In the same preparations, the Walsh 
inhibitor markedly diminishes levels of PKA phosphoryla- 
tion of IP,R. Treatment with cyclosporin A and cyclophilin 
only slightly increases phosphorylation levels and does 
not significantly affect the potency of IP, on Ca*+ flux. 
Membranes phosphorylated by CaMKll display a greater 
potency for IPs in stimulating Ca’+ flux compared with 
membranes treated with peptide [Ala-286]CaMKll(281- 
302), a specific inhibitor of CaMKll (Hvalby et al., 1994). 
Cyclosporin A-cyclophilin only modestly increases 
CaMKll phosphorylation of IP3R further and does not sig- 
nificantly alter IPs effects on Ca*+ flux (Figure 6B). 
Asobserved previously, phosphorylation of purified IP3R 
by PKC is much less than what is observed with PKA and 
CaMKII, although inhibition of this phosphorylation is ob- 
served with PKC(19-36), a specific PKC inhibitor (Hvalby 
et al., 1994). Cyclosporin A-cyclophilin markedly aug- 
ments the PKC phosphorylation of IPaR. Inhibition of PKC 
is associated with a slight but insignificant decrease in IPs 
potency in augmenting Ca*+ flux (Figure 6C). In contrast, 
treatment with cyclosporin A and cyclophilin causes a 
marked augmentation of IPs potency in stimulating CaZ+ 
flux, with the IGO for IPs reduced about 20-fold. The control 
experiment shown in Figure 6D demonstrates that cal- 
change in PKC activity was seen either with calcineurin activation or 
inhibition. 
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cineurin activity itself has no effect on the catalytic activity 
of PKC. Therefore, in our experiments enhancement of 
IPJI phosphorylation by PKC following calcineurin inhibi- 
tion must be due to an inhibition of calcineurin phospha- 
tase activity toward phosphorylated IP$l. 
Thus, phosphorylation by both PKC and CaMKll in- 
creases the potency of IPs in stimulating Ca2+ flux, while 
PKA phosphorylation decreases potency. Most strikingly, 
calcineurin complexed with IP3R appears to be a major 
regulator of the PKC phosphorylation and Ca2+ conduc- 
tance of IP3R, as inhibition of calcineurin by cyclosporin 
A-cyclophilin markedly influences IPs effects on Ca2+ flux 
in PKC-phosphorylated preparations. 
Discussion 
The major finding of the present study is that calcineurin 
is physiologically associated in a physical and functional 
complex with IP$t and FKBP12. Both copurification and 
coimmunoprecipitation experiments support this linkage. 
The association is selectively disrupted by FK.506 and ra- 
pamycin, but not by cyclosporin A. These data imply that 
calcineurin is anchored to IPsR via FKBP12 (as is shown 
in Figure 7). However, we have not ruled out interactions 
of calcineurin with IP3R at a site removed from that of 
FKBPlP binding. In the latter model, the dissociation of 
calcineurin from the IP3R complex caused by rapamycin 
would be secondary to allosteric changes initiated by 
FKBP12 removal. The linkage appears to be Caz+ depen- 
dent, being inhibited by Ca2+-chelating agents. RyR also 
occurs in a complex with calcineurin and FKBP12, which 
is rapamycin and Ca2+ sensitive. RyR-mediated Cazf flux 
activity is regulated via phosphorylation by Ca’+-activated 
kinases (Hain et al., 1995) and it will be interesting to 
determine whether complexed calcineurin regulates RyR 
function as it does for IP3R. 
In the IP3R complex, calcineurin retains its catalytic ac- 
tivity toward known substrates such as MAP-2, and, more 
importantly, it regulates the phosphorylation status of IP3R 
itself. This is most evident for phosphorylation of IP3R by 
PKC, which is barely demonstrable in the absence of cal- 
cineurin inhibition. 
Interestingly, phosphorylation by the different kinases 
varies in effects on Ca2+ flux, with PKC and CaMKll aug- 
menting IPs potency and PKA phosphorylation decreasing 
potency. Zhang et al. (1993) observed that low concentra- 
tions of Ca2+ augment the stimulation by IPs of Ca2+ flux in 
permeabilized fibroblasts, an effect abolished by CaMKll 
inhibitors. This is consistent with our findings that CaMKll 
phosphorylation increases IPs potency in stimulating Cap+ 
flux. Zhang et al. (1993) also observed that high concentra- 
tions of Ca2+ inhibit IPs stimulation of Ca2+ flux and that 
this effect is reversed by FK506, suggesting that with 
higher Ca2+ concentrations calcineurin activity decreases 
IPs effects. Since PKC and CaMKll are the two kinases 
that stimulate IPs actions, presumably the calcineurin inhi- 
bition of flux reflects dephosphorylation of PKC- or CaM- 
KII-phosphorylated sites on IP3R (or both). Our findings 
that the PKC site is much more sensitive to calcineurin 
than the CaMKll site strongly imply that FK506 primarily 
blocks dephosphorylation of a PKC site. 
The IP3R displays a bell-shaped Cap+-sensitive response 
to IPs, with low levels of Caz+ (<300 nM) enhancing IPs- 
stimulated Ca2+ release and higher concentrations (>300 
nM) inhibiting Ca*+ release (lino, 1990). This biphasic re- 
sponse allows for both a positive and negative feedback 
of Ca*+ levels on IP3R-mediated Ca*+ flux and is known to 
be critical for Ca2+ wave propagation that is observed in 
many cell types when stimulated by diverse agonists (Bez- 
prozvanny et al., 1991; Finch et al., 1991; Miyazaki et al., 
1992; for review of Ca*+ oscillations, see Berridge and 
Galione, 1988; Clapham, 1995). From their results, Muel- 
lam and colleagues have suggested that the opposite ef- 
fects of low and high Ca*+ concentrations on IP3-stimulated 
Ca’+ flux might result from differential activation of Ca2+- 
activated kinases and phosphatases (Zhao and Muallem, 
1990; Zhang et al., 1993). Our observations that Ca2+- 
regulated kinases and phosphatases modulate IP3R in a 
Figure 7. Calcineurin Is Associated with lPJR 
via an FKBP12 Anchor in a Ca*+-Sensitive 
Manner 
The figure shows the IP&FKBP12 complex 
in the endoplasmic reticulum membrane. When 
the receptor is activated by IPs, Ca*+ is liberated 
from the endoplasmic reticulum lumen via the 
IP,R channel, and the local cytoplasmic [Ca”] 
increases. This increase results in activation 
of PKC, which phosphorylates the lPJR and fur- 
ther increases IP3R-mediated Ca*+ flux. In- 
creased Ca*+ levels also activate calmodulin 
and calcineurin (CN), causing an association 
of calcineurin with the IP3R-FKBPf2 complex 
via FKBP12 and activation of the phosphatase 
activity of calcineurin. This activation results in 
dephosphorylation of the PKC-phosphorylated 
site on IP,R and a decrease in IP3R-mediated 
Ca*+ flux. The cyclic increases and decreases 
generated by this macromolecular complex 
may mediate Ca2+ oscillations. 
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protein complex provide a potential molecular basis for 
Ca*+ regulation of IP,R and for some aspects of the genera- 
tion of CaZ+ oscillations. Besides phosphorylation by PKA, 
CaMKII, and PKC, IP3R can autophosphorylate as well as 
phosphorylate exogenous substrates (Ferris et al., 1992). 
The existence of kinase and phosphatase in a single mo- 
lecular complex with IP,R provides a means for exquisitely 
modulated, rapid phosphorylation and dephosphorylation 
of IP,R, which regulates its CaZ+ conductance. We propose 
that such influences participate in the fine-tuning of intra- 
cellular Ca*+ dynamics. Whether PKC or other kinases 
occur bound to the same complex as IP3R, FKBP12, and 
calcineurin remains to be determined. 
Ca*+ effects on IP3R function had also been implicated 
by the inhibition of [3H]IP3 binding to IP3R in brain mem- 
branes by iow Ca*+ concentrations (Supattapone et al., 
1988a). The failure of Ca2+ to inhibit [3H]IP3 binding to puri- 
fied IP3R implied the existence of a tissue constituent, 
designated “calmedin,” that conferred Ca2+ effects on IP3R 
and was lost during receptor purification (Danoff et al., 
1988). Other studies suggested that Ca’+ inhibits [3H]IP3 
binding to IP3R in membranes by activating phospholipase 
C to generate IPs, which dilutes added [3H]IP3 (Mignery 
et al., 1992). While those studies may explain some as- 
pects of observed Ca2+ effects on IP3-mediated CaZf re- 
lease, the bell-shaped response of IP3R to Ca2+ is still 
poorly understood and is perhaps clarified by the observed 
association of FKBP and calcineurin with IP3R. 
The influences of phosphorylation of membraneson IP,- 
stimulated Ca2+ flux cannot be ascribed definitively to 
phosphorylation of IPaR. Conceivably, phosphorylation of 
other proteins could indirectly affect IP3R function. How- 
ever, there is a close relationship between the differential 
effects of phosphorylation of IP3R by the three kinases 
and dephosphorylation by calcineurin with actions on Ca*+ 
flux, which strongly implies that the observed changes in 
Ca’+ flux reflect alterations in the phosphorylation status 
of IP3R. 
Our findings provide a molecular mechanism for a 
closely linked phosphorylation-dephosphorylation regula- 
tion of IP3R and presumably of RyR. Dynamic regulation 
of protein function by phosphorylation and dephosphoryla- 
tion is a ubiquitous phenomenon (Hunter, 1995), and in 
other instances the kinase and phosphatase occur in a 
molecular complex with their substrates to ensure fidelity 
of protein phosphorylation (Hubbard and Cohen, 1993). 
Calcineurin can be localized to key neuronal substrates 
at postsynaptic densities by association with the A kinase 
anchoring protein, AKAP79 (Coghlan et al., 1995). Inter- 
estingly, the calcineurin-binding domain identified within 
AKAP79 resembles the domain within FKBPlP known to 
participate in the interaction with calcineurin in the pres- 
ence of FK506 (Aldape et al., 1992). For the calcineurin- 
IP3R-FKBP12 complex, FKBP12 may function analo- 
gously to AKAP79, anchoring a phosphatase, in this case 
calcineurin, to an appropriate substrate, in this case IP3R 
(Figure 7). 
The high affinity and specificity of FK506-FKBP12 inter- 
actions and the role of the drug as “molecular glue” be- 
tween FKBP12 and calcineurin suggests that FK506 mim- 
ics an endogenous protein ligand that physiologically links 
FKBP12 and calcineurin. Consistent with these notions, 
extensive modeling of FK506 has revealed structural simi- 
larities of the drug to the transition state structures for cis- 
Vans isomerization of leucylprolyl and valylprolyl bonds, 
which are also the optimal rotamase substrates for 
FKBPlP (Ikeda et al., 1994; Albers et al., 1990). Our find- 
ings that calcineurin interacts with FKBP12 in a physio- 
logic way via the IP3R-FKBP12 and RyR-FKBP12 com- 
plexes suggest that IP3R and RyR have such “FK506-like” 
peptide domains within their structure, presumably in a 
region of high shared homology between the two recep- 
tors. Using the yeast two-hybrid system, we have recently 
identified the FKBP-binding domain within IP,R and have 
characterized residues critical for the IPaR-FKBP interac- 
tion (A. M. C. and S. H. S., unpublished data). Fleischer 
and colleagues (Timerman et al., 1995) showed that 
FKBP12 mutants lacking rotamase activity modulate Ca*+ 
conductance of RyR as effectively as native FKBP12. This 
suggests that some activity of FKBP12 other than prolyl 
isomerization accounts for its FK506sensitive effects on 
RyR Ca2+ conductance. The anchoring of calcineurin to 
IP3R and RyR by FKBP12, which enables the phosphatase 
activity of calcineurin to modulate channel Ca*+ conduc- 
tance, may be the means whereby FK506 influences 
Ca2+ conductance. Thus, the proposed physiologic role of 
FKBP12 in its complex with calcineurin and the IP3R or 
RyR would be to facilitate the cycle of receptor phosphory- 
lation-dephosphorylation, which in turn would modulate 
Ca*+conductance and participate in the generation of Ca*+ 
oscillations (Figure 7). 
FKBP12 was first identified in T cells to explain the im- 
munosuppressant actions of FK506. Might our present 
findings account for aspects of T cell physiology? Antigen 
stimulation of T cells activates phospholipase C to gener- 
ate IPs. This results in an IP&mediated Ca*+ elevation, 
which enhances calcineurin phosphatase activity toward 
NFAT, permitting its entry into the nucleus and initiation 
of IL-2 transcription (Jayaraman et al., 1995). This eleva- 
tion in cytoplasmic Ca*+ (which at the cell population level 
can be observed to persist for hours) is thought to reflect 
the summation of asynchronous CaZ+ oscillations in indi- 
vidual cells (Lewis and Cahalan, 1989). The persistent os- 
cillatory response seems to be necessary for induction 
of IL-2 transcription (Goldsmith and Weiss, 1988). When 
FKBP12 was first identified, it was proposed as a modula- 
torof ion channels involved in thesignal transduction path- 
way of T cell activation (Siekierka et al., 1989; Harding et 
al., 1989). Upon stimulation of T cells calcineurin moves 
from a freely cytosolic to a membrane-bound form (Chant- 
ler, 1985). Our data imply that FKBP12 functionally links 
calcineurin activity with modulation of IP3R, so that even 
the low levels of FK506 given therapeutically, which are 
sufficient for calcineurin inhibition, would alter IP3R Ca2+ 
conductance as well as inhibit calcineurin activity toward 
other cellular substrates such as NFAT (Figure 7). Further- 
more, the recent demonstration of the presence and partic- 
ipation of RyR in T cell activation (Hakamata et al., 1994) 
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is consistent with the notion of physically associated and 
spatially restricted Ca*+-activated kinases and phospha- 
tases modulating IP3R-FKBP12 and fly!+FKBP12 com- 
plexes to generate Caz+ oscillations and resultant physio- 
logic responses. 
Experimental Procedures 
FPLC 
IP,R was purified as described previously (Ferris et al., 1989) and 
concentrated in Amicon Centriprep-100 concentrators. Concentrated 
IP8 was run on an FPLC Superose 6 gel filtration column in a buffer 
of 250 mM NaCI, 1% CHAPS, 50 mM Tris (pH 7.4) at a flow rate of 
0.2 mllmin, and 1 ml fractions were collected as described previously 
(Cameron et al., 1995). Purified calcineurin was obtained from Sigma, 
resuspended in running buffer as above, and fractionated by FPLC 
identically. Treatment of IP3R with rapamycin during preparation in- 
volved addition of 1 PM final concentration rapamycin to IP3R before 
concentration and inclusion of 1 KM rapamycin in FPLC running buffer. 
Samples were then loaded for SDS-polyacrylamide gel electrophore- 
sis (SDS-PAGE) and visualized by Western blot analysis. 
lmmunoprecipitations 
Crude cerebellar membrane homogenates were prepared as follows: 
rat cerebella were removed and homogenized in a buffer of 50 mM 
Tris (pH 7.4) 1 mM EDTA, 1 mM BME, 0.1 mg/ml leupeptin, 1 mgl 
ml pepstatin, and 0.1 mglml PMSF. The homogenate was centrifuged 
at 45,000 x g for 10 min. The pellet was resuspended in buffer with- 
out BME, solubilized in 1% CHAPS for 20 min, and recentrifuged at 
45,000 x g for 20 min. The supernatant (1 ml) was then used as 
starting material for immunoprecipitation reactions and was treated 
with final concentrations of 100 pM Caz+, 20 mM EGTA, varying con- 
centrations of FK506, rapamycin, or ethanol control vehicle for 4 hr 
at room temperature and then primary antibody or preimmune serum 
for 1 hrat 4O asindicated. Whereindicated, IP,Rantibodywas included 
at 1 Kg/ml, RyRantibody(Affinity Bioreagents)wasincluded at 1 pglml, 
calbindin antibody (SWant) was included at 1 frglml, MAP-2 antibody 
(Sternberger Monoclonals) was included at 1 Kg/ml, and calcineurin 
antibody (Upstate Biotechnology) was included at 1 ~glml. Protein 
G-Sepharose (Pharmacia) was used to precipitate IP3R antibody and 
protein A-Sepharose (Oncogene Science) was used to precipitate 
RyR, MAP-2, calbindin, and calcineurin antibodies. Immunoprecipi- 
tates were washed two times each with PBS plus 1% CHAPS, PBS 
plus1%CHAPSplus0.5M NaCI, and PBS, IoadedforSDS-PAGEand 
subjected to Western blot analysis. Quantification of immunoreactive 
calcineurin band was performed by Adobe Photoshop analysis of mean 
pixel intensity within a standard area containing each band. The value 
of the intensity of the calcineurin band obtained with no FK506 added 
was arbitrarily set at 1 .O and the intensity of the other bands are re- 
ported relative to that. 
Western Blotting Analysis 
Fractions obtained from FPLC or immunoprecipitation were analyzed 
by conventional Western blot analysis using either an antibody specific 
for IP,R (Sharp et al., 1993) at a dilution of l:lO,OOO, an antibody 
specific for calcineurin (Upstate Biotechnology) at adilution of 1:4,000, 
or an antibody specific for RyR (Affinity Bioreagents) at a dilution of 
1:4,000, as recommended. For Western blot analysis, anti-MAP-2 
(Sternberger Monoclonals) and anti-calbindin (SWant) antibodies were 
both used at a dilution of 1:1,000. 
Calcineurin Assay 
Approximately 10 pg of purified MAP-2 was phosphorylated with 50 
U of PKA (Sigma) and 10 pM [32P]ATP (Amersham) at 6000 Cilmmol. 
The phosphorylation reaction was allowed to proceed for 1 hr at 37OC 
and then was stopped by inclusion of 10 KM Walsh inhibitor peptide. 
Phosphorylated MAP-2 was then used as a substrate in a calcineurin 
assay, which typically involved a reaction volume of 100 pl and con- 
tained either 20 mM EGTA, 100 KM Ca2+, 4 PM calmodulin (Sigma), 
1 VM human recombinant FKBP (Sigma), 1 trM FK506, 1 FM rapa- 
mycin, 1 pM cyclosporin A, or 1 PM human recombinant cyclophilin 
(Sigma) as indicated in a buffer of 100 mM NaCI, 50 mM Tris (pH 7.4) 
5 mM DTT, and 10 mM MgCI,. We included 2 pM calcineurin (Sigma) 
or 10 frg of purified IP3R pretreated for 1 hr at room temperature with 
1 PM immunosuppressant or control vehicle, as indicated. Calcineurin 
autoinhibitory peptide (100 PM), deltamethrin (1 nM), permethrin (1 
nM), or okadaic acid (500 nM; all from Biomol) were included as indi- 
cated. Reactions were allowed to proceed for 30 min at 37OC and then 
were stopped with SDS-PAGE sample buffer and loaded for PAGE. 
Gels were dried down and then analyzed by phosphorimager. Quantifi- 
cation of MAP-2 phosphorylation status was determined by the Im- 
ageQuant program and reported as shown. 
Phosphorylation Reactions 
Purified IP,R or microsomal preparations were phosphorylated as de- 
scribed previously (Ferris et al., 1991) except that PKC was obtained 
from Promegaand CaMKll was provided byJ. P. S. Reactions included 
either 10 PM peptide inhibitor, control vehicle, or 1 wLM cyclophilin 
(Sigma) and 1 nM cyclosporin A. 
IPJI Ca*+ Flux Assays 
Rat cerebellar microsomes were prepared as described previously 
(Verma et al., 1992), phosphorylated with cold ATP under conditions 
described above, and assayed for IP3-sensitive “Ca*+ flux as described 
previously (Verma et al., 1992). Cerebellar microsomes take up 45Caz+ 
in a time- and ATP-dependent way, and in a typical assay Ca2+ loading 
plateaus at 250 nmol of Ca2+ per milligram of protein. Free Ca*+ levels 
are determined by using a Ca*+-sensitive electrode (Orion) and are 
titrated to 100 nM by addition of EGTA. Free Ca2+ is spiked with asCa*+ 
to give 100,000 cpm per assay. Total microsome loading is typically 
around 20,000 cpm after an A231 67 (LC Services) blank is subtracted, 
which is typically around 200 cpm. Treatment with the ionophore 
A23187 allows for complete equilibration of Ca2+ and establishment 
of background counts per minute in the absence of loading. This net 
uptake is inhibited in these preparations by releasing 45Ca2+ via the 
IP3R with the addition of increasing concentrations of IPs. Maximal 
concentrations of IPa (10 KM) typically inhibit this total Ca*+ loading 
60%, giving a typical signal of 12,000 cpm for IP,.sensitive stores. 
Treatment of microsomes with submaximal doses of IP, reliably and 
reproducibly inhibits Caz+ loading, from which an I& for IPs inhibition 
of Ca*+ loading can be calculated under a variety of experimental condi- 
tions. Thus, in these experiments, IPs-mediated inhibition of micro- 
some 45Ca2+ uptake is reported as asCan+ flux. Inclusion of 10 pM IPs 
results in approximately 60% inhibition of total a5Can+ uptake (the re- 
maining 40% is loaded into IP3-insensitive pools), and no further inhibi- 
tion of loading is seen with higher concentrations of IPs. This maximal 
release value is reported as 100% Ca*+ flux, and the inhibition seen 
with submaximal concentrations of IPs is reported as a percentage of 
that maximum control. The IPs concentration at which a 50% inhibition 
of loading of this IP3-sensitive Ca2+ pool is observed in replicates of 
three and is reported as I& and can be compared under varying 
conditions of phosphorylation as shown in Figure 6. 
PKC Activity Assay 
A standard assay of PKC catalytic activity was performed as described 
previously (Yasuda et al., 1990) which employed a PKC substrate 
(myelin basic protein, amino acids 4-14; Upstate Biotechnology) that 
is not a substrate for calcineurin phosphatase activity. Calmodulin 
(Sigma) was included at 4 PM, and where indicated calcineurin (Sigma) 
was included at 2 KM, cyclosporin A at 1 PM, and human recombinant 
cyclophilin (Sigma) at 1 PM. In this way the effect of activated or inhib- 
ited calcineurin on PKC activity could be independently assessed. 
PKC activitywas assayed under fourconditionsas listed that examined 
the effect of both activated and inhibited calcineurin, as well as con- 
trolled for the presence of a calcineurin inhibitor. 
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